RESEARCH TRIANGLE PARK, N.C., May 3, 2017 /PRNewswire/ -- Envisia Therapeutics today announced that the Company will present new data for its next generation product candidates, ENV515 for glaucoma and ENV1105 for diabetic macular edema, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium and Congress being held May 5-9, 2017 in Los Angeles, CA. ASCRS is the largest US meeting dedicated exclusively to the needs of the anterior segment specialist.
"Envisia is continuing to make substantial progress in programs focused on glaucoma, diabetic macular edema and our other novel pipeline programs in ophthalmology," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "These are areas in which our approach of combining proven therapeutics with novel PRINT delivery methods can be extremely beneficial for patients. We look forward to sharing our latest clinical results with the scientific community."
Thomas R. Walters, MD, of Texan Eye Care and Keystone Research, Austin, TX will give an oral presentation entitled Nine-Month Duration of Single Use of Low-Dose Extended-Release Travoprost and Matched IOP-Lowering Effects of Pre-Study Prostaglandin Analogs and In-Study Timolol on Sunday May 7th at 8:53am in the LA Convention Center, Meeting Room Level, 410.
Additionally, data from Envisia's ENV1105 program will be presented as an electronic poster entitled Nonclinical Development of an Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema, and will be available for viewing in the ASCRS electronic poster database at the meeting.
ASCRS is a symposium & congress being held jointly with the American Society of Ophthalmic Administrators (ASOA) May 5–9, 2017. ASCRS-ASOA will be the largest U.S. meeting that integrates a scientific program dedicated to the needs of the anterior segment specialist with the leading practice management program for comprehensive ophthalmology and subspecialties. The 2017 ASCRS-ASOA Symposium & Congress will also be a joint meeting with the Asia-Pacific Association of Cataract & Refractive Surgeons.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is currently conducting a phase 2 clinical trial to investigate the safety and tolerability of ENV515 in patients with glaucoma. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
SOURCE Envisia Therapeutics